Prognose

Analytikernes gennemsnitlige kursmål er 45,20 € (+65,87 %). Medianen er 47,62 € (+74,75 %).

Køb	10
Behold	1
Sælg	0

Nyheder Til nyhedsfeedet

Amylyx Pharmaceuticals: stock rises after Avexitide phase-3 success

Amylyx has shifted its business model toward rare niche diseases after the Relyvrio setback. The drug Avexitide delivered convincing phase-3 data, opening access for the company to a previously unserved multibillion-dollar market for postbariatric hypoglycemia. A successful capital raise secures financing well into 2028 and enables the planned commercial launch. As a result, the stock posts a strong gain. » Mere på finanzen.net
Amylyx Pharmaceuticals: phase-3 success with Avexitide reduces severe hypoglycemic events and sends stock sharply higher

In the phase-3 study LUCIDITY, Avexitide reduced postbariatric hypoglycemia events of levels 2 and 3 by 55% versus placebo and met the primary and secondary endpoints agreed with the FDA. This substantially increases the chances of a submission for approval. The news triggered a rally; the stock rose about 65% to a 3.5-year high and continued higher on follow-on buying. » Mere på finanzen.net
Amylyx Pharmaceuticals nears FDA approval after Phase-3 breakthrough with Avexitide

Avexitide reduced hypoglycemia by 55% in the Phase-3 LUCIDITY study, which is being regarded as a decisive breakthrough. Amylyx Pharmaceuticals’ stock rose about 89.6% in one month. The company, which focuses on rare diseases, is thus moving closer to a potential FDA approval for Avexitide. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2018 har AMYLYX PHARMACEUTICALS INC allerede udloddet 0,63 € i udbytte. Den seneste udlodning fandt sted i april 2018.

Virksomhedstal

I det seneste kvartal havde AMYLYX PHARMACEUTICALS INC en omsætning på 0 € og et nettoresultat på -38,05 mio. €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	0	100,00 %
Nettoresultat	-38,05 mio.	8,21 %
EBITDA	-38,01 mio.	8,47 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	3,04 mia. €
Antal aktier	111,19 mio.
Højeste/laveste i 52 uger	35,62 € - 9,38 €
Udbytte	Nej
Beta	-0,20
P/E (PE Ratio)	-22,43
PEG (PEG Ratio)	-0,38
K/I (PB Ratio)	14,70
P/S (PS Ratio)	0,00

Virksomhedsprofil

Amylyx Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entwicklung verschiedener Therapeutika für amyotrophe Lateralsklerose (ALS) und andere neurodegenerative Erkrankungen befasst. Die Produktpipeline des Unternehmens umfasst AMX0035, einen dualen UPR-Bax-Apoptoseinhibitor, der aus Natriumphenylbutyrat und Taurursodiol besteht und zur Behandlung der amyotrophen Lateralsklerose eingesetzt wird. Das Unternehmen entwickelt AMX0035 auch für andere neurodegenerative Erkrankungen. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.